Market cap
$181,182 Mln
Revenue (TTM)
$30,456 Mln
P/E Ratio
17.7
P/B Ratio
15
Div. Yield
2.2 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 12.11 | 10.20 | 5.52 | 3.61 | 2.72 |
| EBIT | -- | -- | 10.34 | 3.07 | 3.19 |
| Net Profit | -619.35 | -635.51 | -151.34 | -189.41 | -189.89 |
| EPS | -623.94 | -640.68 | -152.90 | -184.85 | -191.71 |
| Book Value | -- | -- | 18.01 | 2.54 | 4.62 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 23.53 | 25.86 | 29.71 | 36.75 | 5.80 |
| Net Margin
| -- | 20.27 | -10.64 | -- | -- |
| Return on equity
| 22.83 | 24.38 | -18.77 | 40.49 | 2.28 |
| Return on Capital
| 10.40 | 10.75 | -- | 18.17 | 1.02 |
| Return on Assets
| 8.09 | 8.08 | -5.09 | 14.42 | 0.79 |
| Debt to Equity (x)
| -- | -- | 2.01 | 1.10 | 1.38 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
--
|
18.17
|
1.02
|
12.02
|
9.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-18.77
Lower than Peers by 37.74
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-18.77
|
40.49
|
2.28
|
25.71
|
21.71
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-5.09
Lower than Peers by 7.95
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-5.09
|
14.42
|
0.79
|
9.04
|
7.00
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
29.71
Higher than Peers by 13.89
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
29.71
|
36.75
|
5.80
|
28.05
|
24.74
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-10.64
Lower than Peers by 18.87
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-10.64
|
28.90
|
1.67
|
20.89
|
17.20
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
5.52
Lower than Peers by 2.53
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
5.52
|
0.02
|
0.06
|
-0.01
|
0.00
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
10.34
Higher than Peers by 2.07
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
10.34
|
549.07
|
-78.08
|
12.68
|
-27.27
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-151.34
Lower than Peers by 159.07
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-151.34
|
1,672.92
|
-91.53
|
23.37
|
-26.23
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
-152.90
Lower than Peers by 163.29
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-152.90
|
16.81
|
-0.92
|
0.24
|
-0.26
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
-39.30
Lower than Peers by 44.18
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-39.30
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
2.01
Higher than Peers by 1.42
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
2.01
|
1.10
|
1.38
|
1.09
|
1.19
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.20
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
0.20
|
0.12
|
0.09
|
0.08
|
0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.27
Lower than Peers by 0.38
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
1.27
|
1.55
|
1.60
|
1.43
|
1.29
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
1.09
Lower than Peers by 0.11
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
1.09
|
1.40
|
1.45
|
1.27
|
1.15
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
-0.96
Lower than Peers by 5.73
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
-0.96
|
10.57
|
1.71
|
8.06
|
7.22
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
16.60
Lower than Peers by 4.68
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
16.60
|
16.69
|
15.37
|
17.19
|
17.51
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.48
Higher than Peers by 0.08
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
0.48
|
0.50
|
0.47
|
0.43
|
0.42
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
--
|
57.89
|
57.67
|
63.56
|
62.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
--
|
102.06
|
102.17
|
103.65
|
100.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
--
|
45.35
|
40.40
|
45.78
|
51.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
--
|
114.61
|
119.43
|
121.42
|
110.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
17.74
Lower than Peers by 19.57
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
17.74
|
18.07
|
242.28
|
17.96
|
23.63
|
|
Peer Median
|
37.31
|
--
|
--
|
--
|
--
|
Price / Book Value
15.04
Higher than Peers by 7.28
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
15.04
|
6.77
|
6.02
|
4.46
|
5.11
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
2.24
Higher than Peers by 1.74
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
2.24
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
111.44
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
111.44
|
12.45
|
29.64
|
15.71
|
14.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
181,182
Higher than Peers by 178,592
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
181,182
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,591
|
--
|
--
|
--
|
--
|